| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0001792> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0003253> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0006826> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0026062> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0027651> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0039194> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0086287> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0086582> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0086692> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C0205847> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/33882374_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France. Electronic address: lmansi@chu-besancon.fr.\', \'Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France.\', \'INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Hematology, University Hospital of Besancon, France.\', \'Department of Infectious Disease, University Hospital of Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000, Besançon, France.\', \'Department of Medical Oncology, University Hospital of Besançon, France.\', \'Department of Hematology, University Hospital of Besancon, France.\', \'Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France.\', \'Department of Dermatology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France.\', \'Department of Virology, University Hospital of Besançon, France; Research Unit EA3181, Université de Franche Comté, F-25000 Besançon, France.\', \'INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Pneumology, University Hospital of Besancon, France.\', \'INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France; Department of Pharmacy, University Hospital of Besançon, France.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Adot%C3%A9vi_Olivier> <https://research.tib.eu/covid-19/entity/Almotlak_Hamadi> <https://research.tib.eu/covid-19/entity/Bazan_Fernando> <https://research.tib.eu/covid-19/entity/Borg_Christophe> <https://research.tib.eu/covid-19/entity/Bouard_Adeline> <https://research.tib.eu/covid-19/entity/Bouiller_Kevin> <https://research.tib.eu/covid-19/entity/Daguindau_Etienne> <https://research.tib.eu/covid-19/entity/Jary_Marine> <https://research.tib.eu/covid-19/entity/Kim_Stefano> <https://research.tib.eu/covid-19/entity/Klajer_Elodie> <https://research.tib.eu/covid-19/entity/Kroemer_Marie> <https://research.tib.eu/covid-19/entity/Lepiller_Quentin> <https://research.tib.eu/covid-19/entity/Mansi_Laura> <https://research.tib.eu/covid-19/entity/Meynard_Guillaume> <https://research.tib.eu/covid-19/entity/Nardin_Charl%C3%A9e> <https://research.tib.eu/covid-19/entity/Spehner_Laurie> <https://research.tib.eu/covid-19/entity/Stein_Ulrich> <https://research.tib.eu/covid-19/entity/Vienot_Ang%C3%A9lique> <https://research.tib.eu/covid-19/entity/Westeel_Virginie>
?:doi	<https://research.tib.eu/covid-19/entity/S0959-8049%2821%2900200-810.1016/j.ejca.2021.03.033>
?:doi	S0959-8049(21)00200-810.1016/j.ejca.2021.03.033
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Clinical_Trial> <https://research.tib.eu/covid-19/entity/Journal_Article>
?:journal	European journal of cancer (Oxford, England : 1990)
is ?:pmid of	<https://research.tib.eu/covid-19/entity/33882374>
?:pmid	<https://research.tib.eu/covid-19/entity/33882374>
?:pmid	33882374
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	-1.0
?:rankingScore_hIndex	-1
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C1175175_PROCESS_OF_C1516213> <https://research.tib.eu/covid-19/entity/C1175743_LOCATION_OF_C0033684>
?:title	Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2021

Property

Value

is ?:annotates of

?:authorAffiliation

[\'Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France. Electronic address: lmansi@chu-besancon.fr.\', \'Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France.\', \'INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Hematology, University Hospital of Besancon, France.\', \'Department of Infectious Disease, University Hospital of Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000, Besançon, France.\', \'Department of Medical Oncology, University Hospital of Besançon, France.\', \'Department of Hematology, University Hospital of Besancon, France.\', \'Department of Medical Oncology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France.\', \'Department of Dermatology, University Hospital of Besançon, France; INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France.\', \'Department of Virology, University Hospital of Besançon, France; Research Unit EA3181, Université de Franche Comté, F-25000 Besançon, France.\', \'INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Pneumology, University Hospital of Besancon, France.\', \'INSERM, EFS BFC, UMR1098 RIGHT, University of Bourgogne Franche-Comté, France; Department of Medical Oncology, Biotechnology and Immune-oncology Platforme, University Hospital of Besançon, France; Department of Pharmacy, University Hospital of Besançon, France.\']

?:citedBy